For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 8,589,312 | 6,886,603 | 13,589,740* | 5,324,260 |
| Research and development | 5,659,427 | 5,400,410 | 4,446,974* | 3,666,513 |
| Change in fair value of contingent consideration | -176,500 | -727,500 | 3,000* | 401,500 |
| Loss from operations | 14,072,239 | 11,559,513 | 18,039,714* | 9,392,273 |
| Other income | 4,949,105 | 5,013,557 | 756,387* | 1,797,690 |
| Unrealized loss on marketable securities | -57,032 | -122,838 | - | - |
| Gain on settlement of accounts receivable | - | 152,515 | - | - |
| Net loss | -9,180,166 | -6,516,279 | -17,283,327 | -7,594,583 |
| Cumulative translation adjustment | 5,930 | -10,720 | - | - |
| Comprehensive loss | -9,174,236 | -6,526,999 | - | - |
| Basic EPS | -0.18 | -0.13 | -0.469 | -0.19 |
| Diluted EPS | -0.18 | -0.13 | -0.469 | -0.19 |
| Basic Average Shares | 51,649,161 | 49,807,203 | 36,835,951 | 38,985,143 |
| Diluted Average Shares | 51,649,161 | 49,807,203 | 36,835,951 | 38,985,143 |